Recently, good news came from the Huanggang new production base of Hubei Xindesheng Material Technology Co., Ltd. - all equipment installation work in the new factory has been completed, and key processes such as flaw detection, pressure leakage testing, and single machine debugging have been successfully accepted. This marks the official transition of the project from the construction phase to the system integration debugging and trial production preparation phase, laying a solid foundation for the subsequent full line integration debugging and formal production.
Hubei Xindesheng Huanggang New Production Base is located in the Chemical Industry Park of Huanggang High tech Zone, mainly engaged in the research and production of biological buffering agents and carbomer materials. The project covers an area of approximately 80 acres, with the construction of modern production workshops and related public and auxiliary engineering and environmental protection projects. It plans to develop high-end biological buffering agents such as Tris, Hepes, serum separation gel, as well as pharmaceutical and electronic new material products. After the new factory is fully built and put into operation, it will significantly expand the production capacity of biological buffering agents and IVD core raw materials. The company's scale production capacity, raw material quality control level, and large-scale order delivery ability will achieve a leapfrog improvement.
All equipment installation is in place, and the key process has passed the acceptance inspection
Equipment installation is the core process of chemical project construction. Since the equipment was installed on site, the project team has scientifically organized construction and coordinated progress to ensure that all work is efficiently completed according to the milestones. As of now, all production equipment in the new factory has been installed in place, and dozens of customized large-scale reaction vessels and related supporting equipment have been completed in place and fixed.
After the installation of the equipment was completed, the project team immediately carried out systematic quality inspection work:
Ultrasonic testing: Comprehensive non-destructive testing was conducted on key pressure bearing components such as pressure vessels and pressure pipelines. All welds and connections met the design standards and safety specifications, and the test results were all qualified.
Pressure testing and leakage testing: Strict pressure testing and leakage detection were conducted on all pipeline systems and equipment to ensure that there are no hidden dangers of leakage throughout the production process, and the system's sealing meets the design specifications.
Single machine debugging: Each device has completed no-load and load operation tests, and core parameters such as motor rotation, temperature control accuracy, mixing rate, and smooth feeding and discharging have all met the design requirements. The equipment is operating in good condition.
The successful acceptance of the three key processes mentioned above signifies that the hardware facilities of the new factory are ready for joint testing.
The installation of the self-control system is completed, and the joint debugging and testing are about to end
At the same time as the hardware equipment is in place, the installation of the new factory's automation control system has also been fully completed.
As the "nerve center" of modern chemical production, the self-control system covers the full process automation management from raw material feeding, reaction control, temperature and pressure regulation to finished product packaging. At present, the hardware installation, wiring, and system configuration of all self-control equipment have been completed. The joint debugging and testing work is about to be completed.
After the completion of the joint debugging and testing, the entire production line will achieve an intelligent operation mode of "one click start stop, full process monitoring, abnormal alarm, and automatic adjustment", which not only greatly improves production efficiency, but also effectively ensures the consistency and stability between product batches - this is crucial for fine chemical products such as biological buffers that have strict requirements for purity and batch differences.
The preparation of the trial production plan has been completed and the countdown to production has begun
As a key link in the project's transition from construction to operation, the preparation of the trial production plan has been completed.
The trial production plan covers the entire process operation specifications, process parameter settings, quality control standards, safety emergency plans, and personnel training plans for feeding and testing. In the process of formulating the plan, the technical team fully combined the performance parameters of the new equipment with the rich production experience accumulated by the company in the field of biological buffering agents over the years, and carried out refined design for each step of the operation. The finishing work mainly involves the final confirmation and approval process of some detailed parameters, and is expected to be completed in the near future.
After the completion of the plan preparation, the project will officially enter the trial production stage, and the new factory will welcome the first batch of products to be produced offline.
Leapfrog increase in production capacity helps to localize IVD raw materials
The completion and operation of Huanggang New Factory is of great significance to Hubei Xindesheng and even the entire biological buffer industry.
In terms of production capacity, after the new factory is put into operation, the annual production capacity of biological buffering agents and other products will reach 5000 tons, and the overall production capacity will be significantly increased. The enhancement of large-scale production capacity will effectively ensure the stable supply of large-scale orders from downstream customers.
In terms of quality, the new factory is equipped with advanced automation control system and strict quality inspection system. The product purity can be stably controlled at over 99%, and the difference between batches can be controlled within 1%, which can better meet the increasing demand for high-end biological buffering agents in domestic and foreign markets.
At the industry level, as an important component of IVD in vitro diagnostic core materials, the localization and substitution process of biological buffering agents is accelerating. The commissioning of the new Huanggang plant will further strengthen the domestic ability to independently supply biological buffering agents and help ensure the safety and stability of the industrial and supply chains.
Please stay tuned for further updates on trial production and official production.
Ihre Nachricht muss zwischen 20 und 3.000 Zeichen enthalten!
